Zhao Hongyu
R4MC, AP-10, Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6098, USA.
Drug Discov Today. 2007 Feb;12(3-4):149-55. doi: 10.1016/j.drudis.2006.12.003. Epub 2006 Dec 14.
Hit selection and lead generation are crucial for the success of the resource-demanding lead-optimization phase in drug discovery, and represent a major research area of medicinal chemistry today. Ligand-binding efficiency, ligand complexity, ligand-target profile complementarity and chemical tractability are important parameters in hit selection. As synthesis and assay throughput improve, a large number of analogs based on the same scaffold can be rapidly synthesized and tested. Consequently, more chemistry resources could be devoted to scaffold modifications to expand the candidate pool in lead generation. Most recently discovered druggable targets are promiscuous toward lipophilic ligands, and the hydrophobic portions of hit compounds should be preferentially modified in analog and scaffold design.
命中化合物的筛选和先导化合物的生成对于药物发现中资源需求大的先导化合物优化阶段的成功至关重要,并且是当今药物化学的一个主要研究领域。配体结合效率、配体复杂性、配体-靶点谱互补性和化学可处理性是命中化合物筛选的重要参数。随着合成和检测通量的提高,可以快速合成和测试基于同一骨架的大量类似物。因此,更多的化学资源可用于骨架修饰,以在先导化合物生成中扩大候选化合物库。最近发现的可成药靶点对亲脂性配体具有多特异性,在类似物和骨架设计中应优先修饰命中化合物的疏水部分。